Digest Network Come funziona
Network
/
Società
Ma
Non verificato

Marea Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

12 comunicati stampa

Guarda tutti i comunicati
12/08/2025
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Farmaceutica
Vetrine/Shopping
Salute
Industria
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/08/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Industria
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
14/07/2025
Scienza
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Industria
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/07/2025
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Biologia
Sanità
Farmaceutica
Salute
Mercato del lavoro
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Fiere
Eventi
Industria
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
20/05/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Cardiologia
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/05/2025
Industria
Biotecnologia
Salute
Medicina - Varie
Cardiologia
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/05/2025
Eventi
Industria
Analisi di mercato
Cardiologia
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Scienza
Medicina - Varie
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/04/2025
Eventi
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Sanità
Salute
Farmaceutica
Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/01/2025
Mercato del lavoro
Scienza
Salute
Medicina - Varie
Cardiologia
Biotecnologia
Farmaceutica
Marea Therapeutics Forms Clinical Scientific Advisory Board
Fonte
Marea Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0